We found that MRPL12 knockdown remarkably increased the sensitivity of HCC cells to sorafenib, while MRPL12 overexpression significantly reversed the sensitization effect of lefamulin as indicated by cell viability assays (Figure 4K–N), EDU incorporation and cell apoptosis assays (Figure S4K–N, Supporting Information). Here, MRPL12 is linked to hepatocellular carcinoma.